Pharma largecaps doing well, 3 stocks to bet on: Rahul Shah

Rahul Shah, VP-Equity Advisory, MOFSL, says “in pharma, the largecap numbers so far have been very good and most of the stocks are doing quite well. Obviously, Sun Pharma leads the chart and the numbers were quite good. My sense is, in the entire pharma space, largecaps will continue to do well. Sun is leading the way with Cipla following. In third spot is Dr Reddy’s. So, all three will do well from here.”


Today when I am looking at the markets, certain pharma names are popping up. Whether it is Sun Pharma or Syngene, all are managing to hold on to good gains. Overall, are you looking at pharma as a defensive pack? Pharma has been managing to hold on to some green as well. Are you finding anything exciting in the pharma pack?
Rahul Shah: If you look at it, in the last quarter or two, the market is finding its own space and there has been a sector rotation. If we look at this results season, the investor is going where risk versus reward is quite favourable.


So, in IT, there was a beat in the results and I think most of the IT names have gone up quite sharply post their Q3 numbers. Now it is the turn of pharma. In pharma also, the largecap numbers so far have been very good and most of the stocks are doing quite well. Obviously, Sun Pharma leads the chart and the numbers were quite good.

My sense is, in the entire pharma space, largecaps will continue to do well. Sun is leading the way with Cipla following. In third spot is Dr Reddy’s. So, all three will do well from here.